Export 90 results:
Author [ Title(Asc)] Type Year
Filters: Author is Cruz, F.  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
E
Oliveira, R., Coelho, A., Charrua, A., Avelino, A., & Cruz, F. (2017). Expression of cleaved SNAP-25 after bladder wall injection of onabotulinumtoxina or abobotulinumtoxina: A comparative study in the mice. Neurourology and Urodynamics, 36(1), 86 - 90.
Gorgal, T., Charrua, A., Silva, J. F., Avelino, A., et al. (2012). Expression of apoptosis-regulating genes in the rat prostate following botulinum toxin type a injection. BMC Urology, 12.
Oliveira, R., Botelho, F., Silva, P., Resende, A., et al. (2011). Exploratory study assessing efficacy and complications of TVT-O, TVT-Secur, and Mini-Arc: Results at 12-month follow-up. European Urology, 59(6), 940 - 944.
Antunes-Lopes, T., C. da Silva, M., & Cruz, F. (2016). Evaluation of the Donor After Brain Death and Technique for Organ Procurement. European Urology, Supplements, 15(9), 390 - 396.
Cruz, C. D., & Cruz, F. (2007). The ERK 1 and 2 pathway in the nervous system: From basic aspects to possible clinical applications in pain and visceral dysfunction. Current Neuropharmacology, 5(4), 244 - 252.
Tomada, N., Tomada, I., Botelho, F., Pacheco-Figueiredo, L., et al. (2013). Endothelial function in patients with metabolic syndrome and erectile dysfunction: A question of Angiopoietin imbalance?. Andrology, 1(4), 541 - 548.
Kennelly, M., Dmochowski, R., Schulte-Baukloh, H., Ethans, K., et al. (2017). Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension study. Neurourology and Urodynamics, 36(2), 368 - 375.
Martins-Silva, C., & Cruz, F. (2016). Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: Update of the Pivotal Randomised, Double-blind, Placebo-controlled Trials. European Urology Focus, 2(3), 329 - 331.
Cruz, F., Herschorn, S., Aliotta, P., Brin, M., et al. (2011). Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: A randomised, double-blind, placebo-controlled trial. European Urology, 60(4), 742 - 750.
Montorsi, F., Gandaglia, G., Chapple, C., Cruz, F., et al. (2016). Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: A European phase IV clinical study (SiRE study). International Journal of Urology, 23(7), 572 - 579.
De Carvalho, T. G. R., Pinto, R., Cruz, F., & Silva, J. (2016). Effect of onabotulinum toxin type a intraprostatic injection on the outcome of benign prostatic hyperplasia patients refractory to medical therapy: A 2-year follow-up study. Archivos Espanoles de Urologia, 69(10), 719 - 726.
C
Charrua, A., Reguenga, C., Paule, C. C., Nagy, I., et al. (2008). Cystitis is associated with TRPVIb-downregulation in rat dorsal root ganglia. NeuroReport, 19(15), 1469 - 1472.
Silva, J., Silva, C. M., & Cruz, F. (2014). Current medical treatment of lower urinary tract symptoms/BPH: Do we have a standard?. Current Opinion in Urology, 24(1), 21 - 28.
Chapple, C. R., Cruz, F., Deffieux, X., Milani, A. L., et al. (2017). Consensus Statement of the European Urology Association and the European Urogynaecological Association on the Use of Implanted Materials for Treating Pelvic Organ Prolapse and Stress Urinary Incontinence. European Urology, 72(3), 424 - 431.
Charrua, A., Cruz, C. D., Jansen, D., Rozenberg, B., et al. (2015). Co-administration of transient receptor potential vanilloid 4 (TRPV4) and TRPV1 antagonists potentiate the effect of each drug in a rat model of cystitis. BJU International, 115(3), 452 - 460.
Tomada, N., Tomada, I., Cruz, F., Vendeira, P., & Neves, D. (2010). Characterization of VEGF and angiopoietins expression in human corpus cavernosum during aging. Journal of Sexual Medicine, 7(4 PART 1), 1410 - 1418.
Charrua, A., Pinto, R., Taylor, A., Canelas, A., et al. (2015). Can the adrenergic system be implicated in the pathophysiology of bladder pain syndrome/interstitial cystitis? A clinical and experimental study. Neurourology and Urodynamics, 34(5), 489 - 496.

Pages


Home | Site Map | Contacts | Credits | Privacy & Cookies | Intranet | Social Networks |


rua alfredo allen, 208, 4200-135 porto - portugal | tel +351 220 408 800 | email: info@i3s.up.pt | © copyright 2010 ibmc